Company name Allergan, Inc.
Stock ticker AGN
Live stock price [stckqut]AGN[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Good
Sales growth Good
EPS growth Fair
P/E growth Fair
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $363.76
Target stock price (averages with growth) $361.76
Target stock price (averages with no growth) $164.12
Target stock price (manual assumptions) $328.12

The following company description is from Google Finance: http://www.google.com/finance?q=agn

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates through its two business segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces pharmaceutical products, including: ophthalmic products; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products, and urologics products. The medical devices segment produces a range of medical devices, including: breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Allergan, Inc.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Allergan, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $235.54
  • Growth: 0.175
  • Current EPS (TTM): $5.02
  • P/E: 47
  • Future EPS Calc: $11.24
  • Future Stock Price Calc: $528.43
  • Target stock price: $328.11

[/s2If]
I hope that this makes you a Confident Investor.

Company name Allergan, Inc.
Stock ticker AGN
Live stock price [stckqut]AGN[/stckqut]
P/E compared to competitors Fair

MANAGEMENT EXECUTION

Employee productivity Good
Sales growth Fair
EPS growth Good
P/E growth Fair
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $266.97
Target stock price (averages with growth) $259.81
Target stock price (averages with no growth) $106.31
Target stock price (manual assumptions) $248.31

The following company description is from Google Finance: http://www.google.com/finance?q=agn

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company’s segments include specialty pharmaceuticals, which produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products; and urologic products and the medical devices segment, which produces a range of medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders; obesity intervention products, and facial aesthetics products. In April 2014, TauTona Group’s subsidiary Aline Aesthetics has completed the sale of its Aline hyaluronic acid (HA) thread technology to Allergan, Inc.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Allergan, Inc.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Allergan, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $172.58
  • Growth: 0.18
  • Current EPS (TTM): $4.37
  • P/E: 40
  • Future EPS Calc: $9.99
  • Future Stock Price Calc: $399.9
  • Target stock price: $248.3

I hope that this makes you a better investor. [/s2If]

Company name Magnetek Inc
Stock ticker MAG
Live stock price [stckqut]MAG[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Good
Sales growth Poor
EPS growth Fair
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $27.58
Target stock price (averages with growth) $24.03
Target stock price (averages with no growth) $16.23
Target stock price (manual assumptions) $19.76

The following company description is from Google Finance: http://www.google.com/finance?q=mag

Magnetek, Inc. (Magnetek) is a provider of digital power control systems that are used to control motion and power primarily in material handling, elevator, and energy delivery applications. Its products are sold directly or through manufacturers’ representatives to original equipment manufacturers (OEM) for incorporation into their products, to system integrators and value-added resellers for assembly and incorporation into end user systems, to distributors for resale to OEMs and contractors, and to end-users for repair and replacement purposes. Magnetek’s systems consist primarily of programmable motion control and power conditioning systems used in the applications, such as overhead cranes and hoists; elevators; coal mining equipment, and renewable energy sources. Its customers include the industrial crane and hoist companies in North America and the elevator builders.

 

Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in Magnetek Inc as long as the price is correct. Most of the fundamentals of Magnetek Inc are good, in fact the company ranks as a Good company, but there are some concerns with the price of the stock.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(s2member_level1)]
In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

Stock price at the time of the calculation: $18.45

Growth: 0.12

Current EPS (TTM): $1.29

P/E: 14

Future EPS Calc: $2.27

Future Stock Price Calc: $31.82

Target stock price: $19.76

I hope that this makes you a better investor. [/s2If]

 

Company name Constellation Brands, Inc. Class A
Stock ticker STZ
Live stock price [stckqut]STZ[/stckqut]
Confident Investor Rating Poor

 

The following company description is from Reuters: https://finance.yahoo.com/quote/stz/profile?p=stz

Constellation Brands, Inc., together with its subsidiaries, produces, imports, and markets beer, wine, and spirits in the United States, Canada, Mexico, New Zealand, and Italy. It provides beer primarily under the Corona Extra, Corona Premier, Corona Familiar, Corona Light, Corona Refresca, Corona Hard Seltzer, Modelo Especial, Modelo Negra, Modelo Chelada, Pacifico, and Victoria brands. The company offers wine under the 7 Moons, Drylands, SIMI, Charles Smith, Auros, Kim Crawford, Spoken Barrel, Prisoner, Champagne Palmer & Co, Meiomi, Robert Mondavi, Cooper & Thief, Mount Veeder, Schrader, Crafters Union, Nobilo, Cuvée Sauvage, and Ruffino; and spirits under the Casa Noble, High West, Mi CAMPO, Nelson’s Green Brier, SVEDKA, The Real McCoy brands. It provides its products to wholesale distributors, retailers, on-premise locations, and state alcohol beverage control agencies. The company was founded in 1945 and is headquartered in Victor, New York.

Confident Investor comments: At this price and at this time, I do not think that a Confident Investor can confidently invest in Constellation Brands, Inc. Class A. It is not possible to confidently invest in a company that is not currently profitable.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.

 

Company name Jazz Pharmaceuticals PLC
Stock ticker JAZZ
Live stock price [stckqut]JAZZ[/stckqut]
P/E compared to competitors Good

 

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Good
EPS growth Good
P/E growth Fair
EBITDA growth Good
Price growth Poor
R&D growth Good
Income growth Good
Assets growth Good
Return on Assets growth Good
Income / Rev growth Good
TWCA Plus Good
Standard TWCA Good
Weighted ann. stock price increase Poor

 

ANALYSIS

Confident Investor Rating Fair
Target stock price (TWCA growth scenario) $161.64
Target stock price (averages with growth) $334.31
Target stock price (averages with no growth) $444.8
Target stock price (manual assumptions) $331.8

 

The following company description is from Reuters: https://finance.yahoo.com/quote/jazz/profile?p=jazz

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma. The company was founded in 2003 and is headquartered in Dublin, Ireland.

 

Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in Jazz Pharmaceuticals PLC as long as the price is correct and the indicators that I describe in my book The Confident Investor are favorable. Most of the fundamentals of this company are good but there are some concerns.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Jazz Pharmaceuticals PLC calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $104.68
  • Growth: 0.2
  • Current EPS (TTM): $10.4273737370651
  • P/E: 20.5948436392767
  • Future EPS Calc: $25.94
  • Future Stock Price Calc: $534.36
  • Target stock price: $331.79

[/s2If]
I hope that this makes you a Confident Investor.